Vantage logo

Big caps bounce back for biopharma

Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.

Vantage logo

Are we there yet?

Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.